All In Biotech

Free tool

FAERS Monitor: Cinqair

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761033 or its brand name (Cinqair, Reslizumab). Reports on generic versions are filed under their own applications.

Reports

688

Serious

443

64% of reports

Hospitalization

142

Death reported

17

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea96
  • asthma95
  • incorrect dose administered88
  • drug ineffective83
  • hypertension73
  • cough47
  • headache43
  • wheezing40
  • fatigue39
  • pneumonia33
  • inappropriate schedule of product administration32
  • oropharyngeal pain31
  • myalgia30
  • nausea29
  • chest discomfort27

Reports by year received

View as table
YearReports
20131
20141
201619
201790
201893
201958
202066
202172
202276
202345
202455
202573
202639

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,471 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
asthmaSignal9525.721.32,243
wheezingSignal4020.615.3729
incorrect dose administeredSignal8811.89.7867
hypertensionSignal7310.58.5627
oropharyngeal painSignal3110.27.3250
chest discomfortSignal278.15.6161
inappropriate schedule of product administrationSignal325.43.9112
myalgiaSignal305.43.8104
dyspnoeaSignal965.24.3329
coughSignal475.13.9154
pneumoniaSignal333.12.246
headacheSignal432.11.624
drug ineffective831.91.638
fatigue391.51.17
nausea291.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.